The 3C system models vascular inflammation of the Th1 type, an environment that promotes monocyte and T cell adhesion and recruitment and is antiangiogenic. This system is relevant for chronic inflammatory diseases, vascular inflammation and restenosis.
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The 4H system models vascular inflammation of the Th2 type, an environment that promotes mast cell, basophil, eosinophil, T and B cell recruitment and is pro-angiogenic. This system is relevant for diseases where Th2-type inflammatory conditions play a role such as allergy, asthma, and ulcerative colitis. The BT system models T cell dependent B cell activation and class switching as would occur in a germinal center. This system is relevant for diseases and conditions where B cell activation and antibody production are relevant. These include autoimmune disease, oncology, asthma and allergy.
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Bronchial The CASM3C system models vascular inflammation of the Th1 type, an environment that promotes monocyte and T cell recruitment. This system is relevant for chronic inflammatory diseases, vascular inflammation and restenosis. The HDF3CGF system models wound healing and matrix/tissue remodeling in the context of Th1-type inflammation This system is relevant for various diseases including Fibrosis, Rheumatoid Arthritis, Psoriasis and stromal biology in tumors.
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The KF3CT system models model cutaneous inflammation of the Th1 type, an environment that promotes monocyte and T cell adhesion and recruitment. (Berg et al., 2006; Kunkel et al., 2004a; Kunkel et al., 2004b) . Background levels are ~90-120 AU. Related to Figure 1 In vivo data summary for PF-06297470 (5), PF-06422913 (6) and PF-06462894 (7) in NHP (Palanisamy et al., 2013 Figure 4a . List of test agents that increase cell surface levels of PGE2 (with or without decrease in TNFα) in the BioMAP LPS System, the mechanism of action (if known), active concentrations (nM), evidence for involvement of the compound or class in the regulation of PGE2 (as described in the text), and the reference for skin toxicity or adverse effects. Test agents listed increase in PGE2 in LPS by >20% at two or more concentrations. Note that data for all compounds are included in Supplemental Table S5 .
Related to Figure 4b .
List of test agents that increase levels of soluble IL-2 and IL-6 in the BioMAP BT system, with active concentrations (in nM unless otherwise indicated) and mechanism of action (if known). Listed compounds increase IL-2 and IL-6 >20% compared to vehicle control at two or more concentrations. Data for all compounds are included in Supplemental 
